Gardasil Indications/Uses

QUADRIVALENT HUMAN PAPILLOMAVIRUS (TYPES 6, 11, 16, 18) RECOMBINANT VACCINE (GARDASIL) is a vaccine indicated in girls and women 9 through 45 years for the prevention of cervical, vulvar, vaginal, and anal cancer; precancerous or dysplastic lesions; genital warts; and infections caused by Human Papillomavirus (HPV).
QUADRIVALENT HUMAN PAPILLOMAVIRUS (TYPES 6, 11, 16, 18) RECOMBINANT VACCINE (GARDASIL) is indicated to prevent the following diseases: Cervical, vulvar, vaginal, and anal cancer caused by HPV types 16 and 18; genital warts (condyloma acuminata) caused by HPV types 6 and 11.
And infections and the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, and 18: Cervical intraepithelial neoplasia (CIN) grade 2/3 and Cervical adenocarcinoma in situ (AIS); cervical intraepithelial neoplasia (CIN) grade 1; vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3; vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3; VIN grade 1 and VaIN grade 1; anal intraepithelial neoplasia (AIN) grades 1, 2, and 3.
QUADRIVALENT HUMAN PAPILLOMAVIRUS (TYPES 6, 11, 16, 18) RECOMBINANT VACCINE (GARDASIL) also provides protection in girls and women 9 through 26 years of age against HPV 31-, 33-, 52- and 58-related CIN (grades 1, 2, 3) or AIS.
QUADRIVALENT HUMAN PAPILLOMAVIRUS (TYPES 6, 11, 16, 18) RECOMBINANT VACCINE (GARDASIL) is indicated in boys and men 9 through 26 years of age for the prevention of external genital lesions and infection and the following diseases caused by HPV types included in the vaccine: Anal cancer caused by HPV types 16 and 18; genital warts (condyloma acuminata) caused by HPV types 6 and 11.
And the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, and 18: Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3.